Newron Pharmaceuticals S.p.A.
NP5
Peringkat dalam Saham
#17655
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Harga Saham
$10.89
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$222.65M
Perubahan (1 hari)
2.46%
Perubahan (1 tahun)
-40.10%
Negara
IT
Perdagangan Newron Pharmaceuticals S.p.A. (NP5)
Kategori
Healthcare
Jumlah saham beredar untuk Newron Pharmaceuticals S.p.A. (NP5)
Jumlah saham beredar per October 2026: 0
Menurut laporan keuangan terbaru dan harga saham Newron Pharmaceuticals S.p.A., jumlah saham beredar saat ini adalah 0. Pada akhir October 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Newron Pharmaceuticals S.p.A. (NP5) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| - | - |
CH
|
|
| 62.19M | - |
NL
|
